Kushner Tatyana, Nyabanga Custon T, Cotler Scott J, Etzion Ohad, Dahari Harel
Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Department of Gastroenterology, Mount Sinai Beth Israel, New York, New York, USA.
Open Forum Infect Dis. 2023 Jan 20;10(2):ofad027. doi: 10.1093/ofid/ofad027. eCollection 2023 Feb.
Treating hepatitis C virus (HCV) in pregnancy would address HCV during prenatal care and potentially reduce the risk of vertical transmission. Response-guided therapy could provide a means to individualize and the reduce duration of HCV treatment during pregnancy. Data from a 27-year-old woman indicated that, pretreatment, HCV was stable and that it dropped in a biphasic manner during sofosbuvir/velpatasvir therapy, reaching target not detected at time of delivery-16 days post-initiation of therapy. Mathematical modeling of measured HCV at days 0, 7, and 14 predicted that cure could have been achieved after 7 weeks of sofosbuvir/velpatasvir, reducing the duration of therapy by 5 weeks.
孕期治疗丙型肝炎病毒（HCV）可在产前护理期间解决HCV问题，并有可能降低垂直传播风险。响应导向疗法可为孕期HCV治疗的个体化及缩短疗程提供一种方法。一名27岁女性的数据表明，治疗前HCV稳定，在接受索磷布韦/维帕他韦治疗期间呈双相下降，在治疗开始后16天分娩时达到未检测到目标值。对第0、7和14天测得的HCV进行数学建模预测，索磷布韦/维帕他韦治疗7周后可能实现治愈，疗程缩短5周。
